You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Upsher Smith Labs Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Upsher Smith Labs
International Patents:17
US Patents:8
Tradenames:71
Ingredients:65
NDAs:92

Drugs and US Patents for Upsher Smith Labs

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Upsher Smith Labs BACLOFEN baclofen TABLET;ORAL 074584-002 Aug 19, 1996 AB RX No No ⤷  Subscribe ⤷  Subscribe
Upsher Smith Labs BUMETANIDE bumetanide TABLET;ORAL 209916-001 Jan 23, 2018 AB RX No No ⤷  Subscribe ⤷  Subscribe
Upsher Smith Labs CLOBAZAM clobazam TABLET;ORAL 209687-002 Oct 22, 2018 AB RX No No ⤷  Subscribe ⤷  Subscribe
Upsher Smith Labs JANTOVEN warfarin sodium TABLET;ORAL 040416-009 Oct 2, 2003 AB RX No No ⤷  Subscribe ⤷  Subscribe
Upsher Smith Labs KLOR-CON potassium chloride TABLET, EXTENDED RELEASE;ORAL 019123-001 Apr 17, 1986 AB2 RX Yes No ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 5 of 5 entries

Expired US Patents for Upsher Smith Labs

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Upsher Smith Labs FORTICAL calcitonin salmon recombinant SPRAY, METERED;NASAL 021406-001 Aug 12, 2005 6,440,392 ⤷  Subscribe
Upsher Smith Labs FORTICAL calcitonin salmon recombinant SPRAY, METERED;NASAL 021406-001 Aug 12, 2005 RE40812 ⤷  Subscribe
Upsher Smith Labs FORTICAL calcitonin salmon recombinant SPRAY, METERED;NASAL 021406-001 Aug 12, 2005 RE43580 ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 3 of 3 entries
Paragraph IV (Patent) Challenges for UPSHER SMITH LABS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Nasal Spray 200 IU/spray ➤ Subscribe 2006-03-29
➤ Subscribe Extended-release Capsules 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg ➤ Subscribe 2015-12-24

International Patents for Upsher Smith Labs Drugs

CountryPatent NumberEstimated Expiration
Australia 2014362275 ⤷  Subscribe
European Patent Office 3079703 ⤷  Subscribe
South Korea 20160124930 ⤷  Subscribe
South Korea 102072618 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2014143380 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration
Showing 1 to 5 of 5 entries

Supplementary Protection Certificates for Upsher Smith Labs Drugs

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
2932970 1890039-9 Sweden ⤷  Subscribe PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518
2924034 1990024-0 Sweden ⤷  Subscribe PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE; REG. NO/DATE: EU/1/18/1333 20181126
2822954 LUC00083 Luxembourg ⤷  Subscribe PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625
1441735 SPC/GB08/020 United Kingdom ⤷  Subscribe PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
2822954 SPC/GB18/031 United Kingdom ⤷  Subscribe PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 5 of 5 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.